Postbiotics can be beneficial, but they are not automatically “healthy for everyone.” A potential advantage is that they do not require live microorganisms, which may offer a more predictable safety profile for some users. However, the key issue is standardization: which organism/components, at what dose, and produced by which inactivation process. Without these details, a “postbiotic” claim is weak. Clinically, certain inactivated strains have shown promising results in areas such as immune modulation, reducing susceptibility to respiratory infections, or supporting gut barrier function—yet the strength of evidence varies by outcome. Side effects are often mild (e.g., transient digestive discomfort), but suitability should still be assessed in special populations (immunosuppression, pregnancy, complex chronic disease, or concurrent medications). Bottom line: postbiotics can be a smart, evidence-aligned tool when matched to the right product, dose, and goal—but they are not a miracle; they are a strategic adjunct.